@Tooheys8
Happy to be corrected, I suspect it is basically because it provides 'immediate access' to a much larger patient 'data-set' to move the 'breadth' of the testing/assessments forward far more quickly than waiting (and paying) for access to 'fresh' new-samples as they become available...
Reading between the lines, it seems exosomes have a 'shelf-life' as such, so will basically required UQ & IIQ to 'revert' to basically acquiring access to 'fresh samples' on an ongoing basis to move the test forward (get 'statistical runs' on the board with a significant sample size), collate and then, present to industry, hence the H2FY24 delay-statement...
ML
- Forums
- ASX - By Stock
- Ann: EXO-OC PROGRAM COMPLETES SERUM EQUIVALENCE STUDY
@Tooheys8 Happy to be corrected, I suspect it is basically...
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IIQ (ASX) to my watchlist
|
|||||
Last
55.0¢ |
Change
-0.010(1.79%) |
Mkt cap ! $58.03M |
Open | High | Low | Value | Volume |
56.0¢ | 56.0¢ | 55.0¢ | $25.44K | 46.07K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 23792 | 54.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
55.0¢ | 15741 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 23792 | 0.540 |
2 | 32000 | 0.535 |
1 | 10000 | 0.530 |
4 | 12500 | 0.525 |
5 | 76569 | 0.520 |
Price($) | Vol. | No. |
---|---|---|
0.550 | 15741 | 1 |
0.560 | 10600 | 3 |
0.565 | 3527 | 1 |
0.570 | 4484 | 1 |
0.575 | 10000 | 2 |
Last trade - 14.38pm 02/07/2024 (20 minute delay) ? |
Featured News
IIQ (ASX) Chart |